Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

of RA patients. By blocking the CCR1 ligands including the super-activated forms from interacting with the CCR1 receptor, CCX354 is designed to reduce the migration of inflammatory cells leading to rheumatoid arthritis and subsequently joint destruction.

"CCX354 is the third product candidate to enter the clinic from our discovery platform and marks another important milestone for ChemoCentryx," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "ChemoCentryx has repeatedly shown that it can develop clearly differentiated product candidates by leveraging its technology platform and that it can also advance them expeditiously into clinical development. In less than a year, our product pipeline has expanded from a single ongoing clinical program to now three clinical assets in development."

"We are delighted that this CCR1 antagonist program with ChemoCentryx has progressed to the clinic," said Hugh Cowley, Senior Vice President of GSK's Center of Excellence for External Drug Discovery (CEEDD). "CCX354 may become a promising drug candidate against a number of potential inflammatory diseases and we look forward to seeing the data as it emerges from the clinical trial program."

ChemoCentryx and GSK's Center of Excellence for External Drug Discovery (CEEDD) entered into a multi-product strategic alliance in August 2006 for the discovery, development and commercialization of novel medicines targeting four defined chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders. Under the terms of the agreement, ChemoCentryx is responsible for the discovery and development of up to six small molecule drug candidates across four targets through clinical proof-of-concept, at which point GSK will have exclusive options to license each product for further development and commercialization on a worldwide basis. CCX354 is the second compound under the GSK alliance to enter the clinic. ChemoCentryx's lead com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company ... of implantable lenses and delivery systems for the eye, today ... P. Wall to the Company,s Board. ... a Boston -based investment firm, for more ... the Board of Directors, and chair of the Corporate Governance ...
(Date:9/2/2015)... and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the addition of ... November 26-27, 2015)" conference to their offering. ... key areas of pharmaceutical regulatory affairs in China ... Macau and Taiwan and ... gaining and maintaining a successful Marketing Authorisation in the region ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
(Date:9/2/2015)... ... ... an article published August 12 by International Business Times, a new bill was ... juries in cases meant to decide if a police officer used deadly or excessive force ... Ferguson and New York City that absolved police officers of charges in the deaths of ...
(Date:9/2/2015)... ... , ... Date and time: Oct. 3, 2015, 9 a.m. to 4 p.m. ... Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The Quakertown, ... author Sam Keen based on his new book which he co-authored with his son, ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces its latest addition to its screen mirroring and extending product line -- ... Wireless Display, which operates in local WIFI setting, the new Splashtop Wired XDisplay ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces ... a plus-size actress as the primary love interest in the film. The campaign is ... film, significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Ericson is ... CDI Education Director for HCPro and Associate Director of Education for the Association for ... Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4
... Exercise is known to have a positive effect on maintaining ... of the Journal of Thoracic Oncology has shown ... and secondary prevention of cancer. The Journal of Thoracic ... for the Study of Lung Cancer. Dr. Jennifer Temel at ...
... for All Michigan Residents Will ... recession sends record numbers of Michigan residents onto the ... health insurance, any mid-year cuts to Medicaid would harm ... hospital executives, long-term-care and mental health providers implored the ...
... Media Plays Major Role in Prompting Parent-Teen Discussions ... Dads Have Opportunity to Engage More with KidsNEW ... survey of parents, attitudes about teen drug and ... Partnership for a Drug-Free America and MetLife Foundation. ...
... -- Dr. Hisao Asamura and his team of researchers at ... records of 2,281 patients who underwent lung cancer resection surgery ... May issue of the Journal of Thoracic Oncology , ... of Lung Cancer. Dr. Asamura and his team found that ...
... NASHVILLE, Tenn., May 4 Healthcare Management Systems, Inc.(R) ... as a hospital information technology provider. HMS has ... top HIT vendors; they currently develop, sell and support ... Over the last decade, HMS has expanded its ...
... A new study on old rats by a Penn State ... heart disease and aging in women. , Heart disease is ... of 75. After menopause, women lose their ability to produce ... somehow make women more vulnerable to heart disease and heart ...
Cached Medicine News:Health News:EO Medicaid Cuts Would Harm People 2Health News:EO Medicaid Cuts Would Harm People 3Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 2Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 3Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 4Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 5Health News:Healthcare Management Systems Celebrates 25 Years 2Health News:Penn State professor investigates estrogen, heart disease connection in women 2
... Accurately tests for Nystagmus when ... 10" high by 8" diameter. Light ... ball bearings for effortless spin mechanism. ... from patient. Includes both Adult and ...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Contour design eyelid implants....
Medicine Products: